“Assay”的搜索结果，显示 401-410 项，共有 5553 项

1. 血液科- 临床试验- 妙佑医疗国际

   Rochester, Minn. This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute ...

2. 外科 - 临床试验- 妙佑医疗国际

   Rochester, Minn. The objective of this study is to evaluate the image quality and radiation dose of a CT angiography protocol (CTA) using tube potential ...

3. 血液科- 临床试验- 妙佑医疗国际

   Rochester, Minn. This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute ...

4. 血液科- 临床试验- 妙佑医疗国际

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...

5. 血液科- 临床试验- 妙佑医疗国际

   Rochester, Minn. This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute ...

6. Cookie list for mayoclinic.org - 妙佑医疗国际

   Strictly necessary cookies ; ak_bmsc, Akamai Technologies, This cookie is necessary for Akamai's Bot Manager (to distinguish legitimate users from bots). ; bm_lso ...

7. 血液科- 临床试验- 妙佑医疗国际

   The purpose of this study is to compare epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in ...

8. 乳腺癌精准医疗- 医生与科室- 妙佑医疗国际

   ... assay. Clinical Cancer Research. 2022; doi:10.1158/1078-0432.CCR-22-0203. Couch FJ, et al. Associations between cancer predisposition testing panel genes ...

9. 血液科- 临床试验- 妙佑医疗国际

   Rochester, Minn. This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute ...

10. 血液科- 临床试验- 妙佑医疗国际

    The purpose of this study is to develop and maintain a registry of clinical data and biological specimens from patients with immune system related blood ...